Xenon Pharmaceuticals Inc. (XENE) Financials
XENE Assets vs Liabilities
Date | Assets | Liabilities |
---|---|---|
2023-09-30 | 671.1 million | 34.5 million |
2023-06-30 | 684.9 million | 38.4 million |
2023-03-31 | 719.9 million | 32.9 million |
2022-12-31 | 754.1 million | 32.6 million |
XENE Free Cash Flow and Stock based compensation
Graph available only for supporters. Become a supporter to see it.
Date | Free Cash Flow | Stock based compensation |
---|---|---|
2023-09-30 | -43.4 million | 8.7 million |
2023-06-30 | -35.4 million | 8.5 million |
2023-03-31 | -36.6 million | 6.0 million |
2022-12-31 | -34.5 million | 5.8 million |
XENE Net Income
No data available :(
XENE Cash and Debt
Graph available only for supporters. Become a supporter to see it.
Date | Cash | Debt | Capital Lease |
---|---|---|---|
2023-09-30 | 526.7 million | - | 11.0 million |
2023-06-30 | 539.6 million | - | 11.5 million |
2023-03-31 | 527.0 million | - | 11.6 million |
2022-12-31 | 592.1 million | - | 10.4 million |
XENE Shares Outstanding
XENE Expenses
Graph available only for supporters. Become a supporter to see it.
Date | Capex | R&D | G&A | S&M |
---|---|---|---|---|
2023-09-30 | 1.2 million | 42.9 million | 12.8 million | - |
2023-06-30 | 2.1 million | 44.0 million | 11.6 million | - |
2023-03-31 | 2.2 million | 39.5 million | 9.5 million | - |
2022-12-31 | 1.8 million | 34.8 million | 8.5 million | - |
XENE Cost of Revenue
Graph available only for supporters. Become a supporter to see it.
Date | Revenue | Cost of Revenue |
---|---|---|
2023-09-30 | - | - |
2023-06-30 | - | - |
2023-03-31 | - | - |
2022-12-31 | 8766 | - |
XENE
Price: $42.49
52 week price:
Earnings Per Share: -2.73 USD
P/E Ratio: -18.81
Exchange: NGM
Sector: Healthcare
Industry: Biotechnology
Volume: 730900
Ebitda: -8.5 millionMarket Capitalization: 3.2 billion